A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07492615 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

276

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Sintilimab
DRUG: S-1 & Oxaliplatin

Sponsor

Fudan University